Foster City biotech Geron follows up late-stage trial data with planned $175M stock sale


The company has racked up an accumulated deficit of more than $1 billion over its 32 years.

Previous Highmark Health Plan names new president
Next University of Kansas City Health System finalizes combination with Olathe Health